Role of the mTOR signaling pathway in the rapid antidepressant action of ketamine.
Expert Review of Neurotherapeutics January 2011 DOI: 10.1586/ern.10.176 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Randomized Placebo-controlled Double-blind Peer reviewed |
|---|---|
| Intervention | Ketamine |
| Dose | 0.5 mg/kg |
| Topics | Esketamine Ketamine |
| Key points | The commentary discusses how a single subanesthetic dose of ketamine (0.5 mg/kg) produces rapid antidepressant effects in treatment-resistant major depressive disorder, and contextualizes Li et al.'s findings that the mTOR signaling pathway, involved in protein synthesis and synaptic plasticity, may underlie these effects. |
Abstract
Some patients with major depressive disorder remain resistant to antidepressant medication. A randomized, placebo-controlled, double-blind trial demonstrated that a single subanesthetic dose (0.5 mg/kg) of the N-methyl-D-aspartate receptor antagonist ketamine caused a rapid antidepressant effect within hours in treatment-resistant patients with major depressive disorder. However, the precise cellular mechanisms underlying ketamine's rapid antidepressant actions were unclear, although it is proposed that the α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor might be involved in these mechanisms. Recently, Li et al. reported the role of the mammalian target of rapamycin (mTOR) signaling pathway, a ubiquitous protein kinase involved in protein synthesis and synaptic plasticity, in ketamine's rapid antidepressant effects. Here, these findings are put into context and their significance is discussed.
Citations in the library
Cited by 8
- Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective Psychiatry and Clinical Neurosciences June 19, 2019
- An update on ketamine and its two enantiomers as rapid-acting antidepressants Expert Review of Neurotherapeutics December 4, 2018
- Long-Lasting Antidepressant Action of Ketamine, but Not Glycogen Synthase Kinase-3 Inhibitor SB216763, in the Chronic Mild Stress Model of Mice PLoS One February 4, 2013
- Candidate Strategies for Development of a Rapid-Acting Antidepressant Class That Does Not Result in Neuropsychiatric Adverse Effects: Prevention of Ketamine-Induced Neuropsychiatric Adverse Reactions International Journal of Molecular Sciences October 26, 2020
- Tramadol Pretreatment Enhances Ketamine-Induced Antidepressant Effects and Increases Mammalian Target of Rapamycin in Rat Hippocampus and Prefrontal Cortex BioMed Research International 2012
and 3 more in the library
Cites 9
- A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Archives of General Psychiatry August 1, 2006
- mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists Science August 19, 2010
- A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression Archives of General Psychiatry August 1, 2010
- Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder The Journal of Clinical Psychiatry July 13, 2010
- Glutamatergic Modulators: The Future of Treating Mood Disorders? Harvard Review of Psychiatry August 1, 2010
and 4 more in the library